BrainStorm to test NurOwn in stroke

3 September 2006

BrainStorm Cell Therapeutics, an Israeli drugmaker specializing in central nervous system disorders, says that it is expanding its R&D program to include the treatment of the effects of stroke. The first animal efficacy studies are expected to start in the fourth quarter of the year.

The Tel Aviv-based firm will apply NurOwn, its bone marrow-derived stem cell therapeutic products, to the condition, which strikes over 15 million people worldwide every year, leaving 5.5 million permanently disabled and another 6 million dead.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight